On Monday, Pfizer Inc. (NYSE:PFE)’s shares inclined 1.41% to $32.44.
Pfizer Inc. (PFE) declared the top line results from a Phase 3 study which evaluated the efficacy, safety, and tolerability of Pristiq® (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD).
The study did not meet its primary objective to demonstrate superior efficacy of desvenlafaxine succinate sustained-release formulation contrast to placebo.
This is the second of two Phase 3 placebo controlled studies conducted as part of an FDA post-marketing commitment under the Pediatric Research Equity Act (PREA). Desvenlafaxine did not demonstrate superior efficacy contrast to placebo in either study.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Morgan Stanley (NYSE:MS)’s shares gained 1.28% to $31.69. With its recent share price change, MS market value has reached roughly $60.58 billion. Its most recent quarter balance sheet showed the company is standing at a 1.60 current ratio and possess -0.58 as debt to equity ratio. The company has a Profit Margin (ttm) of positive 22.40% and has 81.50% gross margins. The operating profit margin is 22.40%. The stock’s performance in 1 month is 0.53% and its volatility for the same period is 1.65%.
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The companys Institutional Securities segment offers financial advisory services on mergers and acquisitions, divestitures, joint ventures, corporate restructurings, recapitalizations, spin-offs, exchange offers, leveraged buyouts, takeover defenses, and shareholder relations, in addition to provides capital raising and corporate lending services.
Barclays PLC (ADR) (NYSE:BCS)‘s shares surged 0.78% to $12.97. The last trading range of Barclays PLC (ADR) (NYSE:BCS) ranges between $12.88 and $13.09. The EPS of the company stands at $0.10. The 52-week range shows that the stock reached higher at $18.05 while its lower range is $12.65 in the last 52-weeks. The average volume of the company is at 2.47 million with the Outstanding Shares of 16.78 million. The market capitalization of the company is $54.47 billion. The Beta of the company stands at 1.76 with the RSI (Relative Strength Index) of 40.80.
Barclays PLC, through its auxiliaries, provides various financial products and services worldwide. It offers personal and corporate banking, mortgage, and wealth and investment administration services to individuals and businesses; consumer payments products and services to consumers and merchants; and retail and business banking, corporate and investment banking, and wealth administration and insurance services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.